Toth Financial Advisory Corp Lowers stake in Quest Diagnostics Inc (DGX)

Quest Diagnostics Inc (DGX) : Toth Financial Advisory Corp reduced its stake in Quest Diagnostics Inc by 0.14% during the most recent quarter end. The investment management company now holds a total of 67,544 shares of Quest Diagnostics Inc which is valued at $5,627,766 after selling 97 shares in Quest Diagnostics Inc , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.Quest Diagnostics Inc makes up approximately 1.69% of Toth Financial Advisory Corp’s portfolio.

Other Hedge Funds, Including , Centurylink Investment Management Co reduced its stake in DGX by selling 1,373 shares or 6.58% in the most recent quarter. The Hedge Fund company now holds 19,499 shares of DGX which is valued at $1,624,462. Quest Diagnostics Inc makes up approx 0.56% of Centurylink Investment Management Co’s portfolio.Oregon Public Employees Retirement Fund reduced its stake in DGX by selling 1,862 shares or 5.29% in the most recent quarter. The Hedge Fund company now holds 33,355 shares of DGX which is valued at $2,829,505. Quest Diagnostics Inc makes up approx 0.06% of Oregon Public Employees Retirement Fund’s portfolio. Contravisory Investment Management added DGX to its portfolio by purchasing 222 company shares during the most recent quarter which is valued at $18,832. Quest Diagnostics Inc makes up approx 0.01% of Contravisory Investment Management’s portfolio.Acropolis Investment Management boosted its stake in DGX in the latest quarter, The investment management firm added 325 additional shares and now holds a total of 6,180 shares of Quest Diagnostics Inc which is valued at $519,429. Quest Diagnostics Inc makes up approx 0.10% of Acropolis Investment Management’s portfolio.

Quest Diagnostics Inc closed down -1.52 points or -1.79% at $83.31 with 9,86,206 shares getting traded on Tuesday. Post opening the session at $84.42, the shares hit an intraday low of $83.242 and an intraday high of $84.67 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Quest Diagnostics Inc reported $1.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $1.32. The company had revenue of $1906.00 million for the quarter, compared to analysts expectations of $1905.57 million. The company’s revenue was down -1.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.25 EPS.

Many Wall Street Analysts have commented on Quest Diagnostics Inc. Quest Diagnostics Inc was Initiated by Citigroup to “Neutral” on Sep 9, 2016. Mizuho Downgraded Quest Diagnostics Inc on Aug 31, 2016 to ” Neutral”, Price Target of the shares are set at $86.

Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Company’s other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.

Leave a Reply

Quest Diagnostics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Quest Diagnostics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.